您的位置: 首页 > 媒体报道

《北京周报》査道炯:COVID-19疫苗联合采购新倡议的思考发布时间: 2020-10-29

10月8日,中国同全球疫苗免疫联盟签署协议正式加入“新冠肺炎疫苗实施计划”(COVAX)。“新冠肺炎疫苗实施计划”(COVAX)是由世界卫生组织(WHO)主导,集中了170多个经济体的一项全球疫苗研制合作计划,旨在加快疫苗的开发和生产,并确保每个国家都能公平公正地获得疫苗。


对于此次全球公共卫生挑战,COVAX计划具有重要意义。一方面,该计划参与者占世界人口的70%以上,对于全球经济的复苏至关重要。另一方面,WHO将主导疫苗分发的优先次序,使参与者中的高危人员能及时获得疫苗。同时,各国仍需面对如下挑战:鼓励疫苗开发商提高生产能力,以降低疫苗的运输成本与时间;满足疫苗开发商对知识产权的诉求;使疫苗所需原料的供应链保持开放。


对此,北京大学国际关系学院教授、CIDEG学术委员査道炯在北京周报上发表题为Points to ponder for new initiative for joint sourcing of COVID-19 vaccine 的文章, “清华CIDEG”特将原文转载如下,以飨读者。


To deal with the novel coronavirus disease (COVID-19) pandemic, over 170 economies formed a multilateral arrangement, known as the Covax Facility, in June to secure vaccines in a cost-effective, targeted way.


Proposed by the Global Alliance for Vaccines and Immunisation, Coalition for Epidemic Preparedness Innovations and the World Health Organization (WHO), the facility will seek investment to secure approved vaccines for the most at-risk groups in all participating economies. The Covax Facility is probably the biggest multilateral cooperation initiative since the Paris Agreement on climate change in 2015.


China joined the Covax Facility on October 8, a follow-up on its commitment that any vaccine developed domestically will be made available as an international public good, especially for developing countries. It is also working with a dozen other economies to develop a COVID-19 vaccine via clinical tests and joint manufacturing and distribution.


By October, four out of the nine candidate vaccines in the third and final stages of clinical trial were from China.


A long project

Scientists from around the world started developing vaccines or therapies as soon as Chinese scientists released the sequence of the COVID-19 genome on the Internet in January.


Vaccine development is normally a lengthy process. It can take as long as a decade to ensure a new vaccine is safe and effective before it is approved for public use. So far, close to 100 vaccines are in different stages of development. Once the national regulatory approval is given, WHO will activate its evaluation mechanism for the vaccine's international distribution.


The Covax Facility will pool investment from the participants so that the developers of successful vaccines can begin mass production as soon as possible. The products will then be distributed in a fair and equitable manner among the members.


The higher-income participants will finance the vaccines from their own public finance budgets. They will partner with lower-income members supported by an advance market commitment (AMC) to secure $2 billion by the end of 2020. Contributions to the AMC are expected to come from sovereign donors, philanthropic organizations and the private sector. If the AMC meets its fundraising target, the 92 lower-middle- and low-income participating economies in the facility will benefit.


As China is in the upper tier of middle-income economies on a per-capita basis, it is going to be a self-financing participant. It has reportedly offered to purchase doses to cover the needs of 1 percent of its 1.4-billion population.


This is a sensible move, as China would probably be capable of meeting its needs through its own manufacturing capacities. By keeping open the option of joining the purchase pool, China is in effect making a contribution to the collective effort to increase the COVID-19 vaccine manufacturing potential.


The Covax Facility is an evolving endeavor. On the one hand, its participants represent more than 70 percent of the world's population, including more than half of the Group of 20 economies. Their recovery from the pandemic is essential for the ongoing global economic contraction to end.


On the other hand, the envisioned vaccine delivery capacity is meant for the at-risk segments of those populations. Policies for the prioritization of a vaccine rollout within the economies will be led by WHO. With WHO's expertise in advising economies in need of immunization through vaccination, having the Covax Facility before the products are available is a foresighted approach.


11.jpg

African diplomats visit Sinopharm, a Chinese pharmaceutical company engaged in COVID-19 vaccine research and development in Beijing, on October 15 (XINHUA)


Other challenges

However, to make a safe and effective vaccine available to large segments of the world's population as early as possible, in addition to the Covax Facility, several additional issues need to be addressed.


First, to help bring down per-dose costs, the vaccine developers should be encouraged to enlist manufacturing capacities available worldwide. For example, the Developing Countries Vaccine Manufacturers Network should be roped in to enlarge supplies. If middle- and low-income economies with qualified manufacturers are part of the effort, it will reduce cost and time for cross-border transportation of the products.


Second, vaccine developers' demand to protect their intellectual property rights has to be addressed. Economies wishing to make use of public health exceptions allowed under the World Trade Organization's Trade-Related Aspects of Intellectual Property Rights provisions should ensure that any production under the emergency compulsory license is predominantly for domestic use. This can assuage developers' worries about potential investment loss.


COVID-19 is a national emergency for virtually all economies. Governments of economies with the capacity to produce safe and effective vaccines should see the benefit in encouraging their researchers and manufacturers to be creative in lowering the costs of the products. After all, effective, safe and timely immunization services will help restore normalcy worldwide, which in turn is in the interest of every economy.


Third, to deal with the negative effects of any vaccine nationalism, it should be ensured that the decisions to procure a particular product are made on the basis of science rather than the origin country of the product. Vaccine provision can and in many cases is already part of diplomacy. Yet in the end, there is no higher purpose than giving priority to life.


Last but not least, to prevent any waste of global vaccine manufacturing and distribution capacities, the global supply chains for the needed ingredients should be kept open and free from interference. Faced with the unprecedented global public health challenge, there can be no justification for hoarding.


Source: Beijing Review


学术活动
清华-财新论坛
学术年会
国际会议
学术沙龙
主题论坛
专题研讨
CIDEG竞赛
研究项目
产业发展
环境治理
制度变迁
研究报告
CIDEG政策研究报告
最新研究报告
历年研究报告
专题研究报告
研究团队
研究员
博士后
访问学者
成果出版
CIDEG研究论丛
CIDEG文库
服务经济译丛
服务外包与中国服务业发展丛书
研究通讯
其他出版物
关于CIDEG
CIDEG 新闻
CIDEG 观点
CIDEG简介
组织架构
发展历程
CIDEG年报
联系我们